MCID: ONC002
MIFTS: 53

Onchocerciasis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Onchocerciasis

MalaCards integrated aliases for Onchocerciasis:

Name: Onchocerciasis 12 76 53 59 55 3 44 15 73
River Blindness 53 3
Infection by Onchocerca Volvulus 12
Onchocerca Volvulus Infection 12
Onchocerciasis, Ocular 73
Robles' Disease 53
Volvulosis 12

Characteristics:

Orphanet epidemiological data:

59
onchocerciasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11678
ICD10 33 B73
ICD9CM 35 125.3
MeSH 44 D009855
NCIt 50 C34861
SNOMED-CT 68 38539003
Orphanet 59 ORPHA2737
ICD10 via Orphanet 34 B73
MESH via Orphanet 45 D009855 D015827
UMLS via Orphanet 74 C0029001 C0029002

Summaries for Onchocerciasis

NIH Rare Diseases : 53 Onchocerciasis is a rare tropical parasitic disease transmitted by a black fly. Infection by the parasite can cause eye and skin problems. In humans, the parasitic worms live under the skin (subcutaneous nodules) and produce larvae (microfilariae). The larvae are found throughout the body, but especially in the skin and eyes. Repeated bites by infected flies increase the number of adult worms and larvae. Chronic skin onchocerciasis (onchodermatitis) causes itching, a rash with small pimples (papular rash), scarring, and thickened, leathery skin (lichenification). Other symptoms may develop over time and might include saggy skin (such as ''hanging groin''), patchy areas of much lighter colored skin (leopard skin), ichthyosis-like lesions (''lizard skin''), darkening of the skin, and very severe itching. The eye infection is known as river blindness because the blackfly carrying the parasite lives near fast-flowing waters. Symptoms of an eye infection may include itchy eyes, red eyes, and sensitivity to light (photophobia). In some cases, the larvae may infect the optic nerve. As the common name suggests, infection of the eye by onchocerciasis can lead to vision loss and eventually blindness. The disease is caused by the parasitic worm Onchocerca volvulus and is transmitted by the bite of an infected black fly. About 90% of the cases occur in Africa. Treatment aims to remove the larvae (microfilariae), to improve symptoms, to prevent progression of eye lesions, and to stop the parasite from being passed back to black flies so other people do not become infected. Medications include an anti-parasitic known as ivermectin, antibiotics such as rifampin, azithromycin, and doxycycline, and, another recently approved anti-parasitic drug, Moxidectin.

MalaCards based summary : Onchocerciasis, also known as river blindness, is related to filarial elephantiasis and filariasis. An important gene associated with Onchocerciasis is RBP3 (Retinol Binding Protein 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ivermectin and Anticonvulsants have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes.

Disease Ontology : 12 A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.

CDC : 3  

Wikipedia : 76 Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm... more...

Related Diseases for Onchocerciasis

Diseases related to Onchocerciasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 178)
# Related Disease Score Top Affiliating Genes
1 filarial elephantiasis 31.2 IL4 IL5
2 filariasis 31.1 CCL5 IL2 IL5
3 schistosomiasis 30.2 IL13 IL2 IL4 IL5 RNASE3
4 intestinal volvulus 30.1 CALR IL5
5 wells syndrome 30.1 IL2 IL5 RNASE3
6 dermatitis 29.9 CCL11 IL13 IL4 IL5
7 trypanosomiasis 29.8 CALR CCL5 IL2 IL4
8 tetanus 29.8 IL13 IL2 IL4 IL5
9 skin disease 29.7 CCL11 IL13 IL4 IL5 RNASE3
10 urinary schistosomiasis 29.6 EPX IL13 IL4 IL5 RNASE3
11 malaria 29.6 CCL11 CCL5 IL13 IL2 IL4 IL5
12 parasitic helminthiasis infectious disease 29.4 IL13 IL2 IL4 IL5 RNASE3
13 leishmaniasis 29.3 IL13 IL2 IL4 IL5 MPI
14 loiasis 11.5
15 epilepsy 10.6
16 yemenite deaf-blind hypopigmentation syndrome 10.4
17 scleritis 10.2 IL4 IL5
18 virus associated hemophagocytic syndrome 10.2 IL2 IL4
19 loeffler endocarditis 10.2 IL5 RNASE3
20 egg allergy 10.2 IL4 IL5
21 autoimmune vasculitis 10.2 IL2 IL4
22 sulfamethoxazole allergy 10.2 IL4 IL5
23 trichinosis 10.2 IL4 IL5
24 cow milk allergy 10.2 IL5 RNASE3
25 jak3-deficient severe combined immunodeficiency 10.2 IL2 IL4
26 sinusitis 10.2 IL5 RNASE3
27 non-suppurative otitis media 10.2 IL4 IL5
28 toxic oil syndrome 10.2 IL4 IL5
29 autoimmune gastritis 10.2 IL2 IL4
30 papillary conjunctivitis 10.2 CCL11 IL4
31 eosinophilic granuloma 10.2 EPX RNASE3
32 maxillary sinusitis 10.2 CCL5 RNASE3
33 vulvovaginal candidiasis 10.2 IL2 IL4
34 trachoma 10.2
35 nodding syndrome 10.2
36 conjunctival nevus 10.2 EPX RNASE3
37 eales disease 10.2 IL4 RBP3
38 autoimmune disease of eyes, ear, nose and throat 10.2 CCL5 RBP3
39 pemphigoid gestationis 10.2 CCL11 IL5
40 orofacial granulomatosis 10.1 CCL5 IL4
41 cough variant asthma 10.1 IL4 IL5 RNASE3
42 intrinsic asthma 10.1 IL4 IL5 RNASE3
43 posterior uveitis 10.1 IL2 RBP3
44 chronic meningitis 10.1 CCL11 IL5
45 milk allergy 10.1 IL4 IL5 RNASE3
46 necatoriasis 10.1 CALR IL5
47 gaucher disease, type ii 10.1 IL2 IL4 IL5
48 autoimmune uveitis 10.1 IL2 IL4 RBP3
49 paracoccidioidomycosis 10.1 IL2 IL4 IL5
50 sezary's disease 10.1 IL2 IL4 IL5

Graphical network of the top 20 diseases related to Onchocerciasis:



Diseases related to Onchocerciasis

Symptoms & Phenotypes for Onchocerciasis

Drugs & Therapeutics for Onchocerciasis

Drugs for Onchocerciasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 70288-86-7 6474909
2 Anticonvulsants Phase 4,Phase 2
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
4 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Not Applicable
5
Albendazole Approved, Vet_approved Phase 3,Not Applicable 54965-21-8 2082
6 Vitamins Phase 3,Phase 2
7 Anthelmintics Phase 3,Phase 2,Phase 1,Not Applicable
8 Antiprotozoal Agents Phase 3,Phase 2,Not Applicable
9 Antimitotic Agents Phase 3,Not Applicable
10 Milbemycin Phase 3,Phase 2
11
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
12
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
13
Azithromycin Approved Phase 2 83905-01-5 55185 447043
14
Rifampicin Approved Phase 2 13292-46-1 5458213 5381226
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
16
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
17
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
18
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
19 Vitamin B9 Phase 2
20 Vitamin B Complex Phase 2
21 Neurotransmitter Agents Phase 2
22 Psychotropic Drugs Phase 2
23 Trace Elements Phase 2
24 Central Nervous System Depressants Phase 2
25 GABA Agents Phase 2
26 Diuretics, Potassium Sparing Phase 2
27 Sodium Channel Blockers Phase 2
28 Tranquilizing Agents Phase 2
29 Antimanic Agents Phase 2
30 Vitamin B 6 Phase 2
31 Micronutrients Phase 2
32 Folate Phase 2
33 Antitubercular Agents Phase 2
34 Antibiotics, Antitubercular Phase 2
35 Cytochrome P-450 CYP3A Inducers Phase 2
36 Nucleic Acid Synthesis Inhibitors Phase 2
37 Anti-Bacterial Agents Phase 2
38 Antimalarials Phase 2
39 Artemisinine Phase 2
40 Artemisinins Phase 2
41 Imatinib Mesylate Phase 2 220127-57-1 123596
42 Protein Kinase Inhibitors Phase 2
43
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
44
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
45
Mebendazole Approved, Vet_approved 31431-39-7 4030
46
Piperazine Approved, Vet_approved 110-85-0 4837
47
Diethylcarbamazine Approved, Investigational, Vet_approved ,Not Applicable 90-89-1 3052
48
Citric Acid Approved, Nutraceutical, Vet_approved 77-92-9 311
49
Suramin Investigational 145-63-1 5361
50 Citrate

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Completed NCT03052998 Phase 4 Ivermectin
2 IVM Alone vs ALB + IVM Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
3 Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
4 Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana Active, not recruiting NCT02078024 Phase 3 IVM plus ALB;IVM
5 Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012 Unknown status NCT01730313 Phase 2 Pyridoxine;Sodium Valproate;Phenytoin;Placebo
6 Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
7 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed NCT00127504 Phase 2 Rifampin;Azithromycin
8 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
9 Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
10 Pediatric Pharmacokinetics And Safety Study Of Moxidectin Withdrawn NCT01035619 Phase 2 moxidectin
11 First in Man Clinical Trial of Emodepside (BAY 44-4400) Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
12 Prevalence of LF Infection in Districts Not Included in LF Control Activities Completed NCT03131401
13 Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
14 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
15 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
16 Community Directed Treatment of Soil-Transmitted Helminths Among Young Children in Zambia Completed NCT00349323
17 Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District Recruiting NCT03653975
18 Host Response to Infection and Treatment in Filarial Diseases Recruiting NCT00001230
19 Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis Active, not recruiting NCT02899936 Not Applicable 3 drug dose - IDA;2 drug dose - DA
20 Lymphatic Filariasis (LF) in Ivory Coast Active, not recruiting NCT02974049 Not Applicable Albendazole;Ivermectin;Diethylcarbamazine
21 Ocular Changes After Ivermectin - (DOLF IVM/Oncho) Enrolling by invitation NCT03517462 Not Applicable Ivermectin 3Mg Tab

Search NIH Clinical Center for Onchocerciasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: onchocerciasis

Genetic Tests for Onchocerciasis

Anatomical Context for Onchocerciasis

MalaCards organs/tissues related to Onchocerciasis:

41
Skin, Eye, Testes, Neutrophil, T Cells, B Cells, Lung

Publications for Onchocerciasis

Articles related to Onchocerciasis:

(show top 50) (show all 1104)
# Title Authors Year
1
Audit of the community-directed treatment with ivermectin (CDTI) for onchocerciasis and factors associated with adherence in three regions of Cameroon. ( 29921312 )
2018
2
Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. ( 29348597 )
2018
3
High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20A years of community directed treatment with ivermectin. ( 29921319 )
2018
4
Proof-of-Concept Rapid Diagnostic Test for Onchocerciasis: Exploring Peptide Biomarkers and the Use of Gold Nanoshells as Reporter Nanoparticles. ( 29547260 )
2018
5
Evolution of epilepsy prevalence and incidence in a Tanzanian area endemic for onchocerciasis and the potential impact of community-directed treatment with ivermectin: a cross-sectional study and comparison over 28 years. ( 29605818 )
2018
6
Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis? ( 29210346 )
2018
7
Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes. ( 29966535 )
2018
8
Geographical distribution and species identification of human filariasis and onchocerciasis in Bioko Island, Equatorial Guinea. ( 29289559 )
2018
9
Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world. ( 29642939 )
2018
10
Onchocerciasis prevalence, human migration and risks for onchocerciasis elimination in the Upper Mouhoun, NakambAc and Nazinon river basins in Burkina Faso. ( 29782820 )
2018
11
Modelling the impact of larviciding on the population dynamics and biting rates of Simulium damnosum (s.l.): implications for vector control as a complementary strategy for onchocerciasis elimination in Africa. ( 29843770 )
2018
12
Rethinking the serological threshold for onchocerciasis elimination. ( 29543797 )
2018
13
Interruption of onchocerciasis transmission in Bioko Island: Accelerating the movement from control to elimination in Equatorial Guinea. ( 29723238 )
2018
14
Elimination of onchocerciasis in Ecuador: findings of post-treatment surveillance. ( 29690907 )
2018
15
Evaluation of onchocerciasis control in the Upper Denkyira East municipal in the forest area of Ghana: Responses of participants and distributors to the CDTI programme. ( 29932933 )
2018
16
Report of the first international workshop on onchocerciasis-associated epilepsy. ( 29580280 )
2018
17
Sara Lustigman: Developing a vaccine to accelerate onchocerciasis elimination. ( 29174373 )
2018
18
Corrigendum to: 'Onchocerciasis: the beginning of the end'. ( 29659849 )
2018
19
Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria. ( 29943709 )
2018
20
"Cross-border collaboration in onchocerciasis elimination in Uganda: progress, challenges and opportunities from 2008 to 2013". ( 29409509 )
2018
21
Onchocerciasis associated epilepsy: An important neglected public health problem. ( 29325732 )
2018
22
Impact of five annual rounds of mass drug administration with ivermectin on onchocerciasis in Sierra Leone. ( 29628019 )
2018
23
How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control. ( 29860291 )
2018
24
Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin. ( 30501640 )
2018
25
Community perceptions of epilepsy and its treatment in an onchocerciasis endemic region in Ituri, Democratic Republic of Congo. ( 30509330 )
2018
26
Clinical presentations of onchocerciasis-associated epilepsy (OAE) in Cameroon. ( 30513438 )
2018
27
The effect of bi-annual community-directed treatment with ivermectin on the incidence of epilepsy in onchocerciasis endemic villages in South Sudan: a study protocol. ( 30424817 )
2018
28
Baseline characterization of epilepsy in an onchocerciasis endemic area of the Democratic Republic of Congo. ( 30468846 )
2018
29
High prevalence of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan: A community-based survey. ( 30468964 )
2018
30
Onchocerca volvulus as a risk factor for developing epilepsy in onchocerciasis endemic regions in the Democratic Republic of Congo: a case control study. ( 30293530 )
2018
31
Clinical characteristics of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan. ( 30340162 )
2018
32
Burden of onchocerciasis-associated epilepsy: first estimates and research priorities. ( 30253788 )
2018
33
Onchocerciasis and epilepsy: a causal relationship? ( 30268644 )
2018
34
The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study. ( 30268645 )
2018
35
Onchocerciasis-Associated Epilepsy with Head Nodding Seizures-Nodding Syndrome: A Case Series of 15 Patients from Western Uganda, 1994. ( 30226148 )
2018
36
High prevalence of epilepsy in onchocerciasis endemic health areas in Democratic Republic of the Congo. ( 30064504 )
2018
37
Operationalization of the test and not treat strategy to accelerate the elimination of onchocerciasis and lymphatic filariasis in Central Africa. ( 29471340 )
2018
38
Erratum to: "For as Long as Necessary: Examining 30 years of MSD's Focus on Achieving Elimination of Onchocerciasis and Lymphatic Filariasis". ( 29617827 )
2018
39
Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa. ( 30226900 )
2018
40
Progress toward elimination of onchocerciasis in the Americas. ( 29471334 )
2018
41
After 70 years of fighting an age-old scourge, onchocerciasis in Uganda, the end is in sight. ( 29471335 )
2018
42
Diagnostics for onchocerciasis in the era of elimination. ( 29471336 )
2018
43
The role of national committees in eliminating onchocerciasis. ( 29471337 )
2018
44
The role of the NGDO Coordination Group for the Elimination of Onchocerciasis. ( 29471339 )
2018
45
Onchocerciasis: shifting the target from control to elimination requires a new first-step-elimination mapping. ( 29471341 )
2018
46
Alternative treatment strategies to accelerate the elimination of onchocerciasis. ( 29471342 )
2018
47
Onchocerciasis in Yemen: moving forward towards an elimination program. ( 29471343 )
2018
48
Cross-border issues: an important component of onchocerciasis elimination programmes. ( 29471344 )
2018
49
Establishing quality assured (QA) laboratory support for onchocerciasis elimination in Africa. ( 29471345 )
2018
50
Refocusing vector assessment towards the elimination of onchocerciasis from Africa: a review of the current status in selected countries. ( 29471346 )
2018

Variations for Onchocerciasis

Expression for Onchocerciasis

Search GEO for disease gene expression data for Onchocerciasis.

Pathways for Onchocerciasis

Pathways related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CALR CCL11 CCL5 EPX IL13 IL2
2
Show member pathways
13.68 CCL11 CCL5 CCL7 IL13 IL2 IL4
3
Show member pathways
13.51 CCL11 CCL5 CCL7 IL13 IL2 IL4
4
Show member pathways
13.37 CCL11 CCL5 CCL7 IL13 IL2 IL4
5
Show member pathways
13.25 CCL11 CCL5 CCL7 IL13 IL2 IL4
6
Show member pathways
13.2 CCL11 CCL5 IL13 IL2 IL4 IL5
7
Show member pathways
13.13 CCL11 CCL5 CCL7 IL13 IL2 IL4
8
Show member pathways
12.72 CALR CCL11 CCL5 CCL7
9 12.68 IL13 IL2 IL4 IL5
10
Show member pathways
12.64 CCL5 IL13 IL2 IL4
11
Show member pathways
12.5 CALR CCL11 EPX IL13 IL2 IL4
12
Show member pathways
12.46 IL13 IL2 IL4 IL5
13
Show member pathways
12.27 IL13 IL2 IL4 IL5
14
Show member pathways
12.21 CCL11 CCL7 IL13 IL4 IL5
15
Show member pathways
12.19 CCL11 CCL5 CCL7
16
Show member pathways
12.18 CCL5 IL2 IL4
17
Show member pathways
12.13 IL13 IL2 IL4 IL5
18
Show member pathways
11.92 IL13 IL2 IL5
19
Show member pathways
11.88 CCL11 CCL5 CCL7
20 11.88 IL2 IL4 IL5
21
Show member pathways
11.88 CCL11 CCL5 CCL7 IL13 IL2 IL4
22 11.87 CCL11 IL13 IL4
23 11.73 IL13 IL2 IL4 IL5
24 11.7 IL13 IL2 IL4 IL5
25
Show member pathways
11.65 IL2 IL4 IL5
26 11.62 CCL11 CCL5 IL13 IL2 IL4
27 11.55 CCL11 IL4 IL5
28 11.45 CCL11 CCL5 IL13 IL4 IL5
29 11.43 CCL5 IL13 IL4
30 11.24 IL2 IL4 IL5
31 11.22 IL13 IL4 IL5
32 11.2 IL13 IL2 IL4 IL5
33 11.12 IL13 IL2 IL4 IL5
34 11.11 IL13 IL2
35 11.02 CCL11 IL13 IL2 IL4 IL5
36 10.9 CCL11 CCL5 CCL7 IL13 IL2 IL4
37 10.4 CCL11 CCL5 CCL7 IL13 IL2 IL4

GO Terms for Onchocerciasis

Cellular components related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CALR CCL11 CCL5 CCL7 EPX IL13
2 extracellular space GO:0005615 9.36 CALR CCL11 CCL5 CCL7 EPX IL13
3 cell GO:0005623 9.33 CCL11 CCL7 IL2

Biological processes related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.83 CCL11 CCL5 CCL7 IL13 IL5
2 chemotaxis GO:0006935 9.78 CCL11 CCL5 CCL7
3 cellular response to tumor necrosis factor GO:0071356 9.77 CCL11 CCL5 CCL7
4 cellular response to interferon-gamma GO:0071346 9.75 CCL11 CCL5 CCL7
5 neutrophil chemotaxis GO:0030593 9.73 CCL11 CCL5 CCL7
6 cellular response to interleukin-1 GO:0071347 9.72 CCL11 CCL5 CCL7
7 chemokine-mediated signaling pathway GO:0070098 9.71 CCL11 CCL5 CCL7
8 positive regulation of T cell proliferation GO:0042102 9.69 CCL5 IL2 IL4
9 monocyte chemotaxis GO:0002548 9.67 CCL11 CCL5 CCL7
10 cellular calcium ion homeostasis GO:0006874 9.67 CALR CCL11 CCL5 CCL7
11 lymphocyte chemotaxis GO:0048247 9.63 CCL11 CCL5 CCL7
12 cytokine-mediated signaling pathway GO:0019221 9.63 CCL11 CCL5 IL13 IL2 IL4 IL5
13 negative regulation of endothelial cell apoptotic process GO:2000352 9.62 IL13 IL4
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 CCL5 IL13 IL2 IL4
15 positive regulation of JAK-STAT cascade GO:0046427 9.61 CCL5 IL5
16 positive regulation of T cell differentiation GO:0045582 9.6 IL2 IL4
17 positive regulation of immunoglobulin secretion GO:0051024 9.58 IL2 IL5
18 eosinophil chemotaxis GO:0048245 9.58 CCL11 CCL5 CCL7
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.57 IL2 IL4
20 positive regulation of B cell proliferation GO:0030890 9.56 IL13 IL2 IL4 IL5
21 positive regulation of natural killer cell chemotaxis GO:2000503 9.52 CCL5 CCL7
22 immune response GO:0006955 9.5 CCL11 CCL5 CCL7 IL13 IL2 IL4
23 negative regulation of complement-dependent cytotoxicity GO:1903660 9.48 IL13 IL4
24 regulation of signaling receptor activity GO:0010469 9.17 CCL11 CCL5 CCL7 IL13 IL2 IL4

Molecular functions related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.5 IL2 IL4 IL5
2 cytokine receptor binding GO:0005126 9.37 IL13 IL4
3 chemokine activity GO:0008009 9.33 CCL11 CCL5 CCL7
4 CCR1 chemokine receptor binding GO:0031726 9.26 CCL5 CCL7
5 cytokine activity GO:0005125 9.17 CCL11 CCL5 CCL7 IL13 IL2 IL4
6 CCR chemokine receptor binding GO:0048020 9.13 CCL11 CCL5 CCL7

Sources for Onchocerciasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....